| Name | Title | Contact Details |
|---|
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.
LE JACQ is a Darien, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
For nearly three decades we have been a world leader in the production of bulk Heparin and Pancreatin for the pharmaceutical industry. We have been instrumental in the manufacture and development of pharmaceutical ingredients that have made an enormous
Seasons Center for Behavioral Health is a non-profit organization that provides comprehensive psychiatric and behavioral health services to individuals and families in northwest Iowa.
To enhance the health and well being of our communities through the compassionate delivery of quality healthcare. An organization of caring professionals trusted as our community’s healthcare system of choice for clinical excellence.